

# Claudia Schmoor

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/292236/publications.pdf>

Version: 2024-02-01

69  
papers

3,765  
citations

279798

23  
h-index

161849

54  
g-index

75  
all docs

75  
docs citations

75  
times ranked

5242  
citing authors

#	ARTICLE	IF	CITATIONS
1	Feasibility of an Updated Randomised Controlled Trial on Surgical Urolithiasis Treatments: The Pilot Trial for the German Endoscopic versus Shock Wave Therapy Study (GESS). <i>European Urology Focus</i> , 2022, 8, 271-275.	3.1	1
2	Mastication after craniotomy: pilot assessment of postoperative oral health-related quality of life. <i>Acta Neurochirurgica</i> , 2022, 164, 1347-1355.	1.7	2
3	Prospective multicenter study of the breakable babystent for treatment of aortic coarctation in newborns and infants. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 1529-1537.	1.7	5
4	Survival analysis for Adverse events with VarYing follow-up times (SAVVY): Rationale and statistical concept of a meta-analytic study. <i>Biometrical Journal</i> , 2021, 63, 650-670.	1.0	16
5	Post-Neoadjuvant Surveillance and Surgery as Needed Compared with Post-Neoadjuvant Surgery on Principle in Multimodal Treatment for Esophageal Cancer: A Scoping Review. <i>Cancers</i> , 2021, 13, 429.	3.7	13
6	Oronasal versus Nasal Masks for Non-Invasive Ventilation in COPD: A Randomized Crossover Trial. <i>International Journal of COPD</i> , 2021, Volume 16, 771-781.	2.3	6
7	Portable NIV for patients with moderate to severe COPD: two randomized crossover trials. <i>Respiratory Research</i> , 2021, 22, 123.	3.6	4
8	Estimating and comparing adverse event probabilities in the presence of varying follow-up times and competing events. <i>Pharmaceutical Statistics</i> , 2021, 20, 1125-1146.	1.3	12
9	Survival analysis for Adverse events with VarYing follow-up times (SAVVY) – estimation of adverse event risks. <i>Trials</i> , 2021, 22, 420.	1.6	12
10	Postneoadjuvant surveillance and surgery as needed compared with postneoadjuvant surgery on principle in multimodal treatment for oesophageal cancer: a scoping review protocol. <i>BMJ Open</i> , 2021, 11, e044190.	1.9	0
11	Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation: protocol for a randomised, controlled, open-label intervention, multicentre trial. <i>BMJ Open</i> , 2021, 11, e043345.	1.9	5
12	Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial. <i>ESC Heart Failure</i> , 2021, 8, 4517-4527.	3.1	46
13	Design aspects of COVID-19 treatment trials: Improving probability and time of favorable events. <i>Biometrical Journal</i> , 2021, , .	1.0	6
14	Randomized Phase II Study of All-Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status. <i>Blood</i> , 2021, 138, 2380-2380.	1.4	2
15	Study Protocol of a Prospective Multicenter Study on Patient Participation for the Clinical Trial: Surgery as Needed Versus Surgery on Principle in Post-Neoadjuvant Complete Tumor Response of Esophageal Cancer (ESORES). <i>Frontiers in Oncology</i> , 2021, 11, 789155.	2.8	2
16	Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 – 2, Phase II Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 257-270.	1.6	63
17	Cytopathological Heterogeneity of Circulating Tumor Cells in Non-metastatic Esophageal Adenocarcinoma. <i>Anticancer Research</i> , 2020, 40, 5679-5685.	1.1	5
18	Statistical models for complex data in clinical and epidemiological research. <i>Biometrical Journal</i> , 2020, 62, 528-531.	1.0	0

#	ARTICLE	IF	CITATIONS
19	Whole-brain irradiation with hippocampal sparing and dose escalation on metastases: neurocognitive testing and biological imaging (HIPPORAD) â€” a phase II prospective randomized multicenter trial (NOA-14, ARO 2015â€”3, DTK-ROG). BMC Cancer, 2020, 20, 532.	2.6	43
20	Efficacy of a short-term residential smoking cessation therapy versus standard outpatient group therapy (â€”START-Studyâ€”): study protocol of a randomized controlled trial. Trials, 2020, 21, 562.	1.6	5
21	Relapse- and Immunosuppression-Free Survival after Hematopoietic Stem Cell Transplantation: How Can We Assess Treatment Success for Complex Time-to-Event Endpoints?. Biology of Blood and Marrow Transplantation, 2020, 26, 992-997.	2.0	6
22	Activity of Decitabine (DAC) Combined with All-Trans Retinoic Acid (ATRA) in Oligoblastic AML: Subgroup Analysis of a Randomized 2x2 Phase II Trial. Blood, 2020, 136, 9-10.	1.4	1
23	On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapies. Pharmaceutical Statistics, 2019, 18, 166-183.	1.3	38
24	The Analysis of Adverse Events in Randomized Clinical Trials. , 2019, , 537-557.		3
25	A Wild Bootstrap Approach for the Aalenâ€”Johansen Estimator. Biometrics, 2018, 74, 977-985.	1.4	22
26	The COSTA Study: Sternal Closure in High-Risk Patients - A Prospective Randomized Multicenter Trial. Thoracic and Cardiovascular Surgeon, 2018, 66, 508-516.	1.0	2
27	Multicenter Experience With Mechanical Circulatory Support Using a New Diagonal Pump in 233 Children. Artificial Organs, 2018, 42, 377-385.	1.9	22
28	Sex-Specific Differences in Outcome of Transcatheter or Surgical Aortic Valve Replacement. Canadian Journal of Cardiology, 2018, 34, 992-998.	1.7	23
29	How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care, 2018, 41, 356-363.	8.6	534
30	Clinical evidence for respiratory insufficiency type II predicts weaning failure in long-term ventilated, tracheotomised patients: a retrospective analysis. Journal of Intensive Care, 2018, 6, 67.	2.9	12
31	Psychosocial distress and utilization of professional psychological care in cancer patients: An observational study in <sc>N</sc>ational <sc>C</sc>omprehensive <sc>C</sc>ancer <sc>C</sc>enters (<sc>CCC</sc>s) in <sc>G</sc>ermany. Psycho-Oncology, 2018, 27, 2847-2854.	2.3	37
32	Volumeâ€”outcome relationship in transcatheter aortic valve implantations in Germany 2008â€”2014: a secondary data analysis of electronic health records. BMJ Open, 2018, 8, e020204.	1.9	22
33	A brief instrument to measure health-related quality-of-life in patients with bone metastasis: validation of the German version of Bone Metastases Quality-of-Life-10 (BOMET-QoL-10). Journal of Medical Economics, 2018, 21, 920-929.	2.1	0
34	Multicenter midterm follow-up results using the gore septal occluder for atrial septal defect closure in pediatric patients. Catheterization and Cardiovascular Interventions, 2017, 89, E226-E232.	1.7	19
35	Continuous nonâ€”invasive <sc>PCO<sub>2</sub></sc> monitoring in weaning patients: <sc>T</sc>ranscutaneous is advantageous over endâ€”tidal <sc>PCO<sub>2</sub></sc>. Respiriology, 2017, 22, 1579-1584.	2.3	20
36	Learning Curves Among All Patients Undergoing Transcatheter Aortic Valve Implantation in Germany: A Retrospective Observational Study. International Journal of Cardiology, 2017, 235, 17-21.	1.7	20

#	ARTICLE	IF	CITATIONS
37	DECADE-pilot: decision aid, action planning, and follow-up support for patients to reduce the 10-year risk of cardiovascular diseases—a protocol of a randomized controlled pilot trial. Pilot and Feasibility Studies, 2017, 3, 32.	1.2	6
38	Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology, 2017, 4, e293-e301.	4.6	83
39	Impact of High-Intensity-NIV on the heart in stable COPD: a randomised cross-over pilot study. Respiratory Research, 2017, 18, 76.	3.6	40
40	Capillary PO <sub>2</sub> does not adequately reflect arterial PO <sub>2</sub> in hypoxemic COPD patients. International Journal of COPD, 2017, Volume 12, 2647-2653.	2.3	23
41	ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer, 2016, 16, 503.	2.6	234
42	Adverse event development in clinical oncology trials. Lancet Oncology, The, 2016, 17, e263-e264.	10.7	3
43	Statistical issues in the analysis of adverse events in time-to-event data. Pharmaceutical Statistics, 2016, 15, 297-305.	1.3	47
44	Methodological aspects of the benefit assessment of medical interventions. Biometrical Journal, 2016, 58, 5-7.	1.0	0
45	Safety and tolerability of virucidal hand rubs: a randomized, double-blind, cross-over trial with healthy volunteers. Antimicrobial Resistance and Infection Control, 2015, 4, 37.	4.1	2
46	A-Part Gel, an adhesion prophylaxis for abdominal surgery: a randomized controlled phase II safety study [NCT00646412]. Annals of Surgical Innovation and Research, 2015, 9, 5.	1.3	8
47	DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy. BMC Cancer, 2015, 15, 430.	2.6	47
48	Predictors of prognosis and treatment outcome in central retinal artery occlusion: local intra-arterial fibrinolysis vs. conservative treatment. Neuroradiology, 2015, 57, 1055-1062.	2.2	25
49	Randomized Trial on GvHD Prophylaxis with or without Anti-Human T-Lymphocyte Immunoglobulin ATG-Fresenius (ATG-F) in Allogeneic Hematopoietic Cell Transplantation from Matched Unrelated Donors: Final Long-Term Results after 8.6 Years Median Follow-up. Blood, 2015, 126, 853-853.	1.4	2
50	Home Mechanical Ventilation for COPD: High-Intensity Versus Target Volume Noninvasive Ventilation. Respiratory Care, 2014, 59, 1389-1397.	1.6	41
51	Competing Risks and Multistate Models. Clinical Cancer Research, 2013, 19, 12-21.	7.0	47
52	Prognostic Factors Affecting Outcome after Allogeneic Transplantation for Hematological Malignancies from Unrelated Donors: Results from a Randomized Trial. Biology of Blood and Marrow Transplantation, 2012, 18, 1716-1726.	2.0	55
53	Randomized Trial On GvHD Prophylaxis with or without Anti T Cell Globulin ATG Fresenius (ATG-F) in Allogeneic Hematopoietic Cell Transplantation From Matched Unrelated Donors: Updated Results and Evaluation of the European Group for Blood and Marrow Transplantation (EBMT) Risk Score.. Blood, 2012, 120, 3090-3090.	1.4	0
54	Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood, 2011, 117, 6375-6382.	1.4	281

#	ARTICLE	IF	CITATIONS
55	Correction of confounding bias in non-randomized studies by appropriate weighting. Biometrical Journal, 2011, 53, 369-387.	1.0	16
56	Noninvasive Ventilation in COPD. Chest, 2011, 140, 939-945.	0.8	86
57	Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology, The, 2009, 10, 855-864.	10.7	620
58	Evidence from Nonrandomized Studies: A Case Study on the Estimation of Causal Effects. American Journal of Epidemiology, 2008, 167, 1120-1129.	3.4	41
59	Randomized trial on the effect of radiotherapy in addition to 6 cycles CMF in node-positive breast-cancer patients. , 2000, 86, 408-415.		11
60	Sample size considerations for the evaluation of prognostic factors in survival analysis. , 2000, 19, 441-452.		89
61	Methodological arguments for the necessity of randomized trials in high-dose chemotherapy for breast cancer. Breast Cancer Research and Treatment, 1999, 54, 31-38.	2.5	10
62	Assessment and comparison of prognostic classification schemes for survival data. , 1999, 18, 2529-2545.		584
63	Assessment and comparison of prognostic classification schemes for survival data. Statistics in Medicine, 1999, 18, 2529-2545.	1.6	1
64	A note on estimating local recurrence rates in clinical trials on the treatment of breast cancer. Breast Cancer Research and Treatment, 1998, 49, 87-91.	2.5	14
65	Validation of existing and development of new prognostic classification schemes in node negative breast cancer. Breast Cancer Research and Treatment, 1998, 48, 191-192.	2.5	0
66	Validation of existing and development of new prognostic classification schemes in node negative breast cancer. Breast Cancer Research and Treatment, 1997, 42, 149-163.	2.5	66
67	EFFECTS OF COVARIATE OMISSION AND CATEGORIZATION WHEN ANALYSING RANDOMIZED TRIALS WITH THE COX MODEL. Statistics in Medicine, 1997, 16, 225-237.	1.6	72
68	RANDOMIZED AND NON-RANDOMIZED PATIENTS IN CLINICAL TRIALS: EXPERIENCES WITH COMPREHENSIVE COHORT STUDIES. Statistics in Medicine, 1996, 15, 263-271.	1.6	141
69	Comparison of the cox model and the regression tree procedure in analysing a randomized clinical trial. Statistics in Medicine, 1993, 12, 2351-2366.	1.6	40